Strong year-to-date and third-quarter results drive full-year guidance upgrade

Emma Walmsley, CEO of GSK:

“GSK is delivering strong and sustained performance momentum, with another double-digit growth in sales and earnings. Competitive performance was broad-based but benefited particularly from an excellent launch in the United States alexvi, the world’s first RSV vaccine. Our superior execution supports an upgrade to our full-year 2023 guidance, and we have clear momentum as we look toward our 2026 outlook. GlaxoSmithKline’s long-term prospects also continue to strengthen with progress in its vaccine pipeline, development of its ultra-long-acting HIV portfolio and significant new prospects in the respiratory area. “

Assumptions and Cautionary Statements Regarding Forward-Looking Statements

The management of the Group believes that the above assumptions are reasonable and that the guidance, outlook, ambitions and expectations described in this report can be achieved based on these assumptions. However, given the forward-looking nature of these guidance, outlooks, ambitions and expectations, they are subject to greater uncertainties, including the potential significant impact that may occur if the above assumptions do not materialize, as well as other significant impacts related to foreign exchange fluctuations and macroeconomics. events, outbreaks, the impact of epidemics or epidemics, changes in legislation, regulations, governmental actions or intellectual property protection, product development and approvals, the actions of our competitors and other risks inherent in the industries in which we operate.

This document contains statements that are or may be deemed to be “forward-looking statements.” Forward-looking statements give the Group’s current expectations or forecasts of future events. Investors can identify these statements by the fact that they do not relate strictly to historical or current facts. They relate using words such as “anticipate,” “estimate,” “expect,” “intend,” “will,” “project,” “plan,” “believe,” “goal,” and other words and terms with similar meanings Any discussions regarding future operating or financial results. In particular, these include statements regarding future actions, anticipated products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the results of unanticipated events such as legal proceedings, dividend payments and financial performance. The Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, other than under its legal or regulatory obligations, including the Market Abuse Regulation, the UK Listing Rules and the Financial Conduct Authority’s disclosure and transparency rules. the result of. However, readers should consult any other disclosures the group may make in any documents it issues and/or files with the SEC. All readers, regardless of location, should be aware of these disclosures. Therefore, there can be no assurance that any specific expectations will be met, and investors are cautioned not to place undue reliance on forward-looking statements.

All guidance, outlook, ambitions and expectations should be consistent with guidance, assumptions and
Cautionary Statements in the 2023 Third Quarter Earnings Release and 2022 Annual Report.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors beyond the Group’s control or precise estimation. The Group cautions investors that a number of important factors, including those in this document, could cause actual results to differ materially from those expressed or implied in any forward-looking statements. These factors include, but are not limited to, those discussed in Item 3.D “Risk Factors” of the Group’s 2022 Annual Report on Form 20-F. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based on the knowledge and information available to the directors at the date of this report.

Source link

Leave a Comment